- Home
- CBK vs MREO Comparison
CBK vs MREO Comparison
Compare CBK & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CBK | MREO |
|---|---|---|
| Founded | 1975 | 2015 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 309.9M | 67.5M |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | CBK | MREO |
|---|---|---|
| Price | $25.23 | $0.40 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $3.90 |
| AVG Volume (30 Days) | 31.0K | ★ 2.3M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 1.56% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $6,363.05 |
| P/E Ratio | $9.10 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $23.24 | $0.20 |
| 52 Week High | $27.83 | $2.94 |
Technical Indicators
Market Signals| Indicator | CBK | MREO |
|---|---|---|
| Relative Strength Index (RSI) | 40.32 | 38.92 |
| Support Level | $23.83 | $0.35 |
| Resistance Level | $25.63 | $0.45 |
| Average True Range (ATR) | 0.81 | 0.03 |
| MACD | -0.19 | 0.02 |
| Stochastic Oscillator | 18.63 | 39.87 |
Price Performance
Historical ComparisonAbout CBK Commercial Bancgroup Inc.
Commercial Bancgroup Inc a bank holding company. Through its subsidiary it is a full-service community banking institution that offers traditional consumer and commercial products and services to serve businesses and individuals in select markets in Kentucky, North Carolina, and Tennessee. Its service areas in Tennessee are (i) the Nashville MSA, (ii) the Knoxville MSA, and (iii) the Tri-Cities MSA, and (iv) Claiborne County, Cocke County, Union County, and Hamblen County, and their surrounding areas.
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).